TD Asset Management Inc Acquires 13,402 Shares of Natera, Inc. $NTRA

TD Asset Management Inc boosted its holdings in Natera, Inc. (NASDAQ:NTRA) by 12.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 117,948 shares of the medical research company’s stock after buying an additional 13,402 shares during the period. TD Asset Management Inc’s holdings in Natera were worth $19,926,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Bank of Jackson Hole Trust acquired a new position in shares of Natera in the 1st quarter valued at $29,000. ORG Partners LLC bought a new stake in Natera in the first quarter valued at about $32,000. TCTC Holdings LLC lifted its stake in Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock valued at $33,000 after buying an additional 124 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in Natera by 83.5% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after buying an additional 106 shares during the period. Finally, Hilltop National Bank bought a new position in Natera during the second quarter worth about $33,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In related news, Director Rowan E. Chapman sold 2,750 shares of the business’s stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total value of $459,222.50. Following the sale, the director directly owned 6,015 shares of the company’s stock, valued at approximately $1,004,444.85. The trade was a 31.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 14,083 shares of the company’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $160.00, for a total transaction of $2,253,280.00. Following the completion of the transaction, the chief executive officer directly owned 154,072 shares of the company’s stock, valued at approximately $24,651,520. The trade was a 8.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 72,464 shares of company stock valued at $10,963,125 over the last quarter. 5.63% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $200.00 price target on shares of Natera in a research note on Tuesday. Evercore ISI upgraded shares of Natera to a “strong-buy” rating and set a $170.00 price objective for the company in a report on Monday, July 28th. Piper Sandler reiterated an “overweight” rating and issued a $220.00 target price (up from $210.00) on shares of Natera in a report on Monday, August 11th. Stephens reissued an “overweight” rating and set a $183.00 price target on shares of Natera in a research report on Friday, August 15th. Finally, Morgan Stanley restated an “overweight” rating and issued a $195.00 price objective on shares of Natera in a research report on Sunday, August 10th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $196.81.

Natera Price Performance

NASDAQ:NTRA opened at $181.69 on Friday. Natera, Inc. has a fifty-two week low of $117.27 and a fifty-two week high of $187.34. The stock has a market capitalization of $24.94 billion, a PE ratio of -95.13 and a beta of 1.74. The business’s 50-day simple moving average is $168.19 and its 200-day simple moving average is $158.35.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The business had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. Natera’s revenue for the quarter was up 32.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. On average, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.